Guilt by association: EcDNA as a mobile transactivator in cancer

Trends Cancer. 2022 Sep;8(9):747-758. doi: 10.1016/j.trecan.2022.04.011. Epub 2022 Jun 23.

Abstract

Extrachromosomal DNA (ecDNA), first described in the 1960s, is emerging as a prevalent but poorly characterized oncogenic alteration in cancer. ecDNA is a reservoir for oncogene amplification and is associated with an aggressive tumor phenotype and poor patient outcome. Despite the long-held knowledge of its existence, little is known about how ecDNA affects tumor cell behavior. Recent data reveal that ecDNA hubs are mobile transcriptional enhancers which can transactivate gene expression through chromatin interactions. Given its prevalence, structural complexity, and unequal segregation into daughter cells, ecDNA can offer selective growth advantages, contribute to intratumor heterogeneity (ITH), and accelerate tumor evolution. Future technology development is expected to transform the current paradigm for studying ecDNA and lead to therapeutic strategies targeting ecDNA vulnerabilities.

Keywords: cancer genome variation; chromatin interactions; ecDNA hubs; extrachromosomal circular DNA; mobile activators; superenhancers.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Chromatin / genetics
  • DNA, Circular* / genetics
  • DNA, Mitochondrial* / genetics
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • Oncogenes
  • Trans-Activators* / genetics

Substances

  • Chromatin
  • DNA, Circular
  • DNA, Mitochondrial
  • Trans-Activators